PBYI News and Press, Puma Biotechnology Inc From 11/05/20

Puma Biotechnology (PBYI): Q3 Non-GAAP EPS of -$0.60 misses by $0.46; GAAP EPS of -$0.79 misses by $0.40.Revenue of $50.8M (-9.9% Y/Y) misses by $2.17M.Shares -7.9%.Press Release For further details see: Puma Biotechnology EPS misses by $0.46, misses on revenue

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor (EGFR) exon 18 mutations that has been previous...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2020. Unless otherwise stated, all comparisons are for the third quarter of 2020 compared to the third quarter of 2019. Product revenue, net co...

Puma Biotechnology (NASDAQ:PBYI) is scheduled to announce Q3 earnings results on Thursday, November 5th, after market close.The consensus EPS Estimate is -$0.14 (-16.7% Y/Y) and the consensus Revenue Estimate is $52.97M (-6.1% Y/Y).Over the last 2 years, PBYI has beaten EPS estimates 100% of ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:15 p.m. EST on Tuesday, November 10, at the Credit Suisse 29th Annual Hea...

Puma Biotechnology reports positive Neratinib Phase III data. Y-mAbs Therapeutics receives FDA rejection for omburtamab BLA. Halozyme Therapeutics fortifies collaboration with Argenx for Enhanze technology. For further details see: Puma's Positive Neratinib Data, And Oth...

Puma Biotech (PBYI) is up 1% after hours after announcing results from a 2,840-subject Phase 3 clinical trial, ExteNET, evaluating Nerlynx (neratinib), after neoadjuvant and/or adjuvant therapy with chemotherapy and trastuzumab, in patients with HER2-positive early-stage breast canc...

Data published online in Clinical Breast Cancer Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC) from the Phase III ExteNE...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:30 a.m. EDT on Tuesday, Sept. 15, at the H.C. Wainwright 22 nd Annual Global ...

MONTREAL, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced filing of the Supplement to a New Drug Submission (SNDS) of NERLYNX for HER2-Positive Metastatic Breast Cancer in Canada. NERLYNX...